Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (4): 473-478.

Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药

张新然¹, 张弋¹, 高慧儿¹, 强兆艳², 李咏梅^3*

1.天津市第一中心医院药学部,天津 300192;
2.天津医科大学基础医学院药理学系,天津 300070;
3.天津医科大学基础医学院病原生物学系,天津 300070

收稿日期:2019-06-17 修回日期:2019-11-04 出版日期:2020-04-05 发布日期:2020-04-06
通讯作者: *liym@tmu.edu.cn
基金资助:
国家自然科学基金青年科学基金(81800165)

Shc3 over-expression inhibits apoptosis of HCC cells and is involved in drug resistance

ZHANG Xin-ran¹, ZHANG Yi¹, GAO Hui-er¹, QIANG Zhao-yan², LI Yong-mei^3*

1. Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192;
2. Department of Pharmacology, Basic Medicine College, Tianjin Medical University, Tianjin 300070;
3. Department of Pathogen Biology, Basic Medicine College, Tianjin Medical University, Tianjin 300070, China

Received:2019-06-17 Revised:2019-11-04 Online:2020-04-05 Published:2020-04-06
Contact: *liym@tmu.edu.cn

摘要/Abstract

摘要： 目的探讨Shc3对人肝细胞癌HCC细胞凋亡及耐药机制。方法选取稳定下调Shc3的人肝细胞癌系HCCLM3和HepG2细胞及其对照组scramble细胞,稳定上调Huh7和HepG2细胞及其对照组pCDH细胞。Western blot检测Shc3、MEK、p-MEK、ERK和p-ERK蛋白表达;real-time PCR检测Shc3 mRNA表达;凋亡实验检测细胞凋亡;CCK-8法检测细胞增殖。结果成功验证Shc3降表达及过表达细胞系;与scramble组比较,Shc3降表达组细胞MEK/ERK通路激活程度明显降低(P＜0.05),细胞凋亡比例增加(P＜0.05);与pCDH组比较,Shc3表达上调增加细胞对索拉菲尼耐受性(P＜0.05),并且MEK/ERK通路激活程度明显增强(P＜0.05)。结论 Shc3可通过干扰HCC细胞凋亡,激活MEK/ERK通路,增加HCC细胞对索拉菲尼的耐药性,本研究结果为靶向Shc3治疗肝细胞癌提供了理论依据和实验室基础。

关键词: 人肝细胞癌, Shc3, 细胞凋亡, 细胞耐药

Abstract: Objective To investigate the apoptosis and drug resistance mechanism of Src homolog and collagen homolog 3 (Shc3) in human hepatocellular carcinoma (HCC). Methods Human hepatocellular carcinoma cell lines HCCLM3 and HepG2 with stable Shc3 downregulation and their scramble cell control groups were selected, Huh7 and HepG2 cells with stable Shc3 up-regulation and their pCDH control groups were selected. Protein expression levels of Shc3,MEK,p-MEK,ERK and p-ERK were determined by Western blot analysis. The mRNA level of Shc3 were determined by real-time PCR. Apoptotic experiment was used to observe cell apoptosis. CCK-8 assays were used to observe cell proliferation. Results Shc3 down-regulation and up-regulation cell lines were proved. Compared with scramble cells, Shc3 down-regulation significantly decreased activity of MEK/ERK pathway (P＜0.05), promoted cell apoptosis significantly (P＜0.05). Compared with pCDH cells, Shc3 up-regulation increased cell tolerance to sorafenib (P＜0.05), Moreover, significantly enhanced activity of MEK/ERK pathway (P＜0.05). Conclusions Shc3 may increase the resistance of HCC cells to sorafenib by interfering with apoptosis of HCC cells and activating MEK/ERK pathway. The results of this study provide theoretical basis and laboratory basis for targeting at Shc3 in the treatment of hepatocellular carcinoma.

Key words: human hepatocellular carcinoma, Shc3, cell apoptosis, cell resistance

中图分类号:

R739.41

张新然, 张弋, 高慧儿, 强兆艳, 李咏梅. Shc3高表达抑制人肝癌细胞系凋亡并参与肝癌耐药[J]. 基础医学与临床, 2020, 40(4): 473-478.

ZHANG Xin-ran, ZHANG Yi, GAO Hui-er, QIANG Zhao-yan, LI Yong-mei. Shc3 over-expression inhibits apoptosis of HCC cells and is involved in drug resistance[J]. Basic & Clinical Medicine, 2020, 40(4): 473-478.

参考文献

[1]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66:115-132.
[2]Llovet JM, Burroughs A, Bruix J. Hepatocellular carcino-ma[J]. Lancet, 2003, 362: 1907-1917.
[3]Liu Y, Zhang XR, Yang BC, et al. Demethylation-induced overexpression of Shc3 interacts with MVP and activates MEK/ERK independent of c-Raf[J]. Cancer Res, 2018, 78:2219-2233.
[4]Miyake I, Ohira M, Nakagawara A, et al. Distinct role of ShcC docking protein in the differentiation of neuroblas-toma[J]. Oncogene, 2009, 28: 662-673.
[5]Sun JX, Shi J, Li N, et al. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma[J]. Cancer Biol Med, 2016, 13:452-458.
[6]Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma[J]. Hepatology, 1998, 27:951-958。
[7]张新然,强兆艳,庄昊,等. GDF15表达下调促进人胶质母细胞瘤细胞系U87MG增殖[J]. 基础医学与临床,2017,37:1557-1561.
[8]De Falco V, Guarino V, Malorni L, et al. RAI (ShcC/N-Shc)-dependent reemitment of GAB1 to RET oncoproteins potentiates PI3-K signaling in thyroid tumors[J]. Oncogene, 2005, 24: 6303-6313.
[9]Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activa-tion of Ras and Jak/Stat pathways in human HCC[J]. Gastroenterology, 2006, 130: 1117-1128.
[10]Yang QS, Jiang LP, He CY, et al. Up-Regulation of microRNA-133a inhibits the MEK/ERK signaling pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in esophageal cancer in vivo and in vitro[J]. J Cell Biochem, 2017, 118: 2625-2634.
[11]Raoul JL, Adhoute X, Gilabert M, et al. How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma[J]. World J Hepatol, 2016, 8: 1541-1546.
[12]Mazzoccoli G, Miele L, Oben J, et al. Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib[J]. Curr Drug Targets, 2016, 17:783-799.
[13]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851-11858.

[1]	江宁郭钧. 莪术醇通过Wnt/β-catenin信号通路对人骨肉瘤细胞增殖、凋亡作用[J]. 基础医学与临床, 2022, 42(8): 120-1205.
[2]	薛晋芳宋海飞陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[3]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[4]	雷家秀, 朱雅萍, 张雨. 依托咪酯上调miR-290-5p减轻LPS诱导的大鼠心肌细胞系H9C2损伤[J]. 基础医学与临床, 2021, 41(6): 848-853.
[5]	王伟, 赵四林, 范伏元, 金朝晖, 李妲, 符艳. 下调miR-199a-5p抑制脂多糖诱导的大鼠Ⅱ型肺泡上皮细胞系AECⅡ凋亡[J]. 基础医学与临床, 2021, 41(4): 521-527.
[6]	胡惟恺, 刘瑞霞, 阴赪宏. 人端粒酶反转录酶线粒体转位的研究进展[J]. 基础医学与临床, 2021, 41(12): 1818-1822.
[7]	尤旭, 朱小芳, 胡运鹏, 龚杨, 赵磊. 黄芪总皂苷对心衰大鼠心肌细胞凋亡和线粒体膜电位的影响[J]. 基础医学与临床, 2020, 40(9): 1218-1223.
[8]	周丽萍, 毛晓春, 李琴. miR-1908抑制高糖诱导的人视网膜血管内皮细胞系HRECs凋亡[J]. 基础医学与临床, 2020, 40(8): 1090-1095.
[9]	潘姝, 文丹宁, 李华东. miR-29b通过调控Bax基因抑制LPS诱导的肺泡上皮细胞系A549凋亡[J]. 基础医学与临床, 2020, 40(6): 797-802.
[10]	吴友明, 刘娜斯, 曹明月, 黄薇, 刘雁勇, 杨楠. Hsp90靶向抑制多肽P7与多西他赛联用对肺腺癌细胞系A549的协同抗肿瘤作用[J]. 基础医学与临床, 2020, 40(5): 639-643.
[11]	王然然, 姜双全, 李守强, 于丹丹, 冷晓萍. 半乳糖凝集素-7生物学功能研究进展[J]. 基础医学与临床, 2020, 40(3): 399-402.
[12]	杨崛圣, 樊虎熊, 胡姗, 高日峰, 卢飞, 王恒, 唐燕华. TRPM7干扰载体修复低氧/复氧致大鼠心肌细胞系H9C2损伤[J]. 基础医学与临床, 2020, 40(2): 209-214.
[13]	童静凯江霞. 托伐普坦对小鼠内髓集合管细胞系水通道蛋白及肾小管功能的影响[J]. 基础医学与临床, 2019, 39(8): 1163-1167.
[14]	晋瑞金迎迎李嫚雷喆. 过表达脾酪氨酸激酶降低氧化应激诱导的小鼠成骨细胞凋亡[J]. 基础医学与临床, 2019, 39(7): 1013-1018.
[15]	张娟冯燕和水祥. 过表达miR-5195-3p对结直肠癌细胞凋亡的影响[J]. 基础医学与临床, 2019, 39(3): 385-391.